Inhibition of the mTOR and MAPK pathways in the treatment of osteosarcoma Kathleen M. Diehl, M.D. FACS Assistant Professor University of Michigan.

Slides:

Advertisements

Similar presentations

Clinical developmentDiscovery Typical development timeline Typically – 8 yearsTypically 7 years.

Advertisements

1 Results of the Phase 3, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus as maintenance therapy in advanced sarcoma patients.

21th WCC, Shenzhen, China, Aug 19, 2010 Guo-Liang Jiang, MD, FACR Min Fan, MD, Jiayan Chen, MD Fudan University Shanghai Cancer Center Combination of radiation.

ER stress is partially responsible for BN108- and TspA3- induced apoptosis C. D. E. F. Figure 3. A. Western blot analysis of the levels of phosphorylated.

HCVM Member of  -herpesvirus family >200 ORFs Genes are expressed in a regulated cascade Some fulfill regulatory functions pUL38 expression during early.

Cell Division and Apoptosis III Chapter 17. Activation of a cyclin dependent kinase.

PI-103 in Chordoma Joseph Schwab, Cristina Antonescu, John Healey, Patrick Boland, G. Petur Nielsen, Andrew Rosenberg, Edwin Choy, David Harmon, Thomas.

Targeting the IGF Pathway in Pediatric Sarcomas-Lessons Learned and Questions Raised Lee J. Helman, M.D. Scientific Director for Clinical Research,Center.

Student Research Interest HER2 Receptor Signaling in Breast Cancer Cells Marc Y. Fink Biomedical Sciences LIU-Post.

Advanced Cancer Topics Journal Review 4/16/2009 AD.

Kyoto University, Japan

Gene Transcription G0G0 G1G1 Priming S G2G2 M Cell Cell Cycle Growth Factors + Growth Factors & Cell Cycle Receptors.

Isosteviol derivatives induced apoptosis in Human lung cancer via targeting MEK/MAPK pathway: An in vitro and in vivo study Ahmed M Malki 1,,PhD Stephen.

CLU inhibition using OGX-011 synergistically enhances Zol activity in osteosarcoma François Lamoureux, Marc Baud’huin, Benjamin Ory, Martin E. Gleave,

 Angiogenesis Signaling Cascades EGFR PI3K MAPK Nucleus Gene Activation Cell Cycle Progression M G1G1 S G2G2 Fos P P MAPK = mitogen-activated protein.

Ρύθμιση κυτταρικού κύκλου & Εισαγωγή στην κυτταρική σηματοδότηση Γιώργος Ρασιδάκης Επ. Καθηγητής Παθολογικής Ανατομικής, Ιατρική Σχολή ΕΚΠΑ Adj. Assistant.

Effects of metformin and thymoquinone on survival of leukemic cells

Specialized signaling pathways 1: RTK associated pathways

Bio 714 Foster TGF-beta/cell cycle material. Points: Suppression of either PLD or mTOR in the absence of serum results in apoptosis Importantly, suppression.

12 th Annual CTOS Meeting 2006 AP23573 Induced Long-term Stability in 2 Patients with Desmoplastic Small Round Cell Tumor (#561) Scott Schuetze, Warren.

Restriction Point G0 TGF-  and Cell Cycle Progression Cyclin D CDK4/6 Cyclin E CDK2 TGF-  Cell Growth Checkpoint G1-pm SG1-psG2M.

Insulin and Amino Acid Signaling Through mTOR in Perfused Rat Liver Jessica Biegler.

The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma by Thomas E. Witzig,

Defining Epidermal Growth Factor Receptor exon 20 mutant sensitivity to tyrosine kinase inhibition Danny Rayes.

Kui Wang May 6th, 2017.

Inducible EGFR T790M-Mediated Gefitinib Resistance in Non-small Cell Lung Cancer Cells Does Not Modulate Sensitivity to PI103 Provoked Autophagy Flavia.

Enhanced Sensitivity to Sunitinib by Inhibition of Akt1 Expression in Human Castration- resistant Prostate Cancer PC3 Cells Both In Vitro and In Vivo

The CDK4/6 Inhibitor Palbociclib induces anti-proliferative Mechanisms in Gastroenteropancreatic Neuroendocrine Neoplasms in vitro. *F. Briest1,2,3, *I.Grass1,2,

Presented By Luca Malorni at 2017 ASCO Annual Meeting

Strategies for differential inhibition of mTORC1 and mTORC2 with rapamycin. Strategies for differential inhibition of mTORC1 and mTORC2 with rapamycin.

Cyclin-Dependent Kinase 2 Promotes Tumor Proliferation and Induces Radio Resistance in Glioblastoma Jia Wang, Tong Yang, Gaofeng Xu, Hao Liu, Chunying.

Dual Inhibition of PI3K/AKT and MEK/ERK Pathways Induces Synergistic Antitumor Effects in Diffuse Intrinsic Pontine Glioma Cells Y. Linda Wu, Uday Bhanu.

Program Goals. Targeting New Pathways for Overcoming Endocrine Resistance in Breast Cancer.

Proangiogenic stimulation of bone marrow endothelium engages mTOR and is inhibited by simultaneous blockade of mTOR and NF-κB by Lara F. Costa, Mercedes.

Ming Hong Shen, Paulina Samsel, Louise L

Figure 4 Possible combination therapies CDK4/6 inhibitors

Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma Darshil J. Shah, MD, MPH, Roxana S. Dronca,

P90RSK Blockade Inhibits Dual BRAF and MEK Inhibitor-Resistant Melanoma by Targeting Protein Synthesis Nicholas Theodosakis, Goran Micevic, Casey G.

Volume 10, Issue 2, Pages (August 2006)

Figure 1 A schematic representation of the HER2 signalling pathway

Volume 67, Issue 3, Pages e4 (August 2017)

Cell Physiol Biochem 2016;39: DOI: /

Figure 1 mTOR complex biology

Volume 29, Issue 3, Pages (March 2016)

Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer Vassiliki Papadimitrakopoulou,

Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase.

Mechanical stretch induces podocyte hypertrophy in vitro1

Inducible EGFR T790M-Mediated Gefitinib Resistance in Non-small Cell Lung Cancer Cells Does Not Modulate Sensitivity to PI103 Provoked Autophagy Flavia.

Proliferation of cancer cells despite CDK2 inhibition

Kavitha Gowrishankar, Stephanie Snoyman, Gulietta M. Pupo, Therese M

Taru Muranen, Funda Meric-Bernstam, Gordon B. Mills Cancer Cell

by Reuben Kapur, Ryan Cooper, Lei Zhang, and David A. Williams

SOX4 Promotes Proliferative Signals by Regulating Glycolysis through AKT Activation in Melanoma Cells Wei Dai, Xinyuan Xu, Shuli Li, Jingjing Ma, Qiong.

Volume 21, Issue 4, Pages (February 2006)

Potent Dual Inhibitors of TORC1 and TORC2 Complexes (KU and KU ) Demonstrate In Vitro and Ex Vivo Anti-Keloid Scar Activity Farhatullah.

A novel class I histone deacetylase inhibitor, I-7ab,

Volume 32, Issue 1, Pages (October 2008)

Coactivation of Receptor Tyrosine Kinases in Malignant Mesothelioma as a Rationale for Combination Targeted Therapy Marie Brevet, MD, PhD, Shigeki Shimizu,

mTOR and Akt Signaling in Cancer: SGK Cycles In

Simon Ekman, MD, PhD, Murry W. Wynes, PhD, Fred R. Hirsch, MD, PhD

Volume 32, Issue 1, Pages (October 2008)

Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

Volume 67, Issue 3, Pages e4 (August 2017)

Phases of the Cell Cycle

Phases of the Cell Cycle

Schematic representation of signaling pathways associated with cannabinoid receptor activation induced by its agonists. Schematic representation of signaling.

Quercetin induces autophagy, blocks cell cycle and activation of ERK and JNK signaling pathways participates in the G1 arrest in P39 cells. Quercetin induces.

Giulia Tarantola, Humanitas University

Presentation transcript:

Inhibition of the mTOR and MAPK pathways in the treatment of osteosarcoma Kathleen M. Diehl, M.D. FACS Assistant Professor University of Michigan

Background Osteosarcoma cell lines –SAOS-2, COL, OS-187 Rapamycin –Sirolimus –Natural macrolide antibiotic (anti-fungal) –Binds to FKBP12 inhibiting mTORC1 –Analogues CCI-779 (Wyeth) RAD001 (Novartis) AP23573 (Ariad)

Clinical Trials CCI-779 –I/II lung, breast, neuroendocrine, uterine, cervical, soft tissue sarcomas –III (RCCA) –PR 7-9% –SD 26-36% RAD001 –I/II, RCCA, solid tumors –PR 5-33% –SD % –Very high PR or SD rate soft tissue sarcoma AP23573 –I/II hematologic, solid tumors, sarcoma –PR 3-11% –SD 25% –100% of sarcoma patients had PR or SD –56% clinical improvement

PI3k IFG-1 Growth Factor Receptors Nutrients Hypoxia Stress PTEN IRS Ras bRaf ERK1/2 (p-MAPK) Proliferation Akt p70 s6K Survival and Cell Cycle Progression MEK1/2 TSC 1/2 Rheb AKT 4EBP mTOR TORC1 mTOR TORC2 elF4E uo-126 Rapamycin

IC50 Comparing Sensitivity Between Cell Lines

Flow Cytometry of Cells Treated for 48 hrs with Rapamycin

Decrease in cell cycle proteins cyclin D1 and cdk4 in OS-187 cells A B C A B C ControlTreated A = Cyclin D1 B = cdk4 C = Cyclin D3

Western blot 4EBP Cont hr24 hr p-4EBP 4EBP Cont hr24 hrs p-4EBP1 4EBP1 Cont hr 24 hrs p-4EBP1 4EBP1 COL OS-187 SAOS-2

Western blot 70S6k Note: lack of activity in COL and OS187 cells confirmed with 2-D gels for T389 and T at hrs. Cnt 1hr 8hr 24hr 1hr 8hr 24hr 1hr 8hr 24hr 50nM100nM200nM p-70 S6k 70 S6k Cont hr 24 hrs p-70 S6k 70 S6k Cont 24hrs8hrs1hr p-70 S6k 70 S6k COL OS-187 SAOS-2

Summary Treatment Osteosarcoma Cells with Rapamycin Concentration dependent decrease in cell growth and proliferation Associated with G1 arrest but not apoptosis Cell line dependent decrease in the phosphorylation of proteins of the mTOR pathway Decrease in cell cycle proteins

Proliferation Assays showing effectiveness of uo-126 in decreasing proliferation in these cells COL OS-187 SAOS-2

uo-126 Synthesized, in-vitro use Inhibits active and inactive MEK1/2 of the Mitogen Activated Protein Kinase Pathway Cellular proliferation

COL

OS-187 cells

SAOS-2 cells

2-phase Flow Cytometry showing apopotosis with the addition of uo-126 to Rapa in COL and OS-187 cells OS-187 Control OS-187 Rapa OS-187 Rapa uo-126 COL Control COL Rapa COL Rapa uo-126

Summary The addition of the MAPK pathway inhibitor uo-126 to Rapamycin resulted in –Synergistic decrease in proliferation in COL and OS-187 cells –Additive decrease in proliferation in SAOS-2 cells –Apoptosis

Conclusions The combination of inhibition of the mTOR and MAPK pathways shows promise for the treatment of osteosarcoma

Next Steps Confirmation with in-vivo model Comparison with inhibitors of other cell survival and proliferation pathways Comparison with other mTOR inhibitors

Acknowledgements Laurence BakerLaurence Baker Qi Wu Zhiyu Wang Dafydd Thomas Rashmi Chugh Kenine Comstock Carolyn Hoban Scott Schuetze David Lucas

Thank You